275 related articles for article (PubMed ID: 23045411)
1. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J; van Egmond PW; Helder MN; de Menezes RX; Cleton-Jansen AM; Beliën JA; Verheul HM; van Royen BJ; Kaspers GJ; van Beusechem VW
Oncotarget; 2012 Oct; 3(10):1169-81. PubMed ID: 23045411
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.
Lin Z; Song D; Wei H; Yang X; Liu T; Yan W; Xiao J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):239-46. PubMed ID: 26276504
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of neuropilin-1 suppresses invasion, angiogenesis, and increases the chemosensitivity to doxorubicin in osteosarcoma cells - an in vitro study.
Yue B; Ma JF; Yao G; Yang MD; Cheng H; Liu GY
Eur Rev Med Pharmacol Sci; 2014; 18(12):1735-41. PubMed ID: 24992616
[TBL] [Abstract][Full Text] [Related]
8. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M; Duan PG; Gao ZZ; Dai M
Oncol Rep; 2020 Dec; 44(6):2691-2700. PubMed ID: 33125503
[TBL] [Abstract][Full Text] [Related]
10. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
11. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
Zhang Y; Duan G; Feng S
Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
[TBL] [Abstract][Full Text] [Related]
13. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
Zhang CL; Zhu KP; Shen GQ; Zhu ZS
Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
[TBL] [Abstract][Full Text] [Related]
14. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.
Roos A; Satterfield L; Zhao S; Fuja D; Shuck R; Hicks MJ; Donehower LA; Yustein JT
Br J Cancer; 2015 Nov; 113(9):1289-97. PubMed ID: 26528706
[TBL] [Abstract][Full Text] [Related]
15. CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.
Li X; Xu R; Liu H; Fang K
Tumour Biol; 2016 Jun; 37(6):8139-44. PubMed ID: 26715273
[TBL] [Abstract][Full Text] [Related]
16. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells.
Zhang F; Chen A; Chen J; Yu T; Guo F
Asian Pac J Cancer Prev; 2011; 12(1):239-45. PubMed ID: 21517265
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma.
Sun X; Tian C; Zhang H; Han K; Zhou M; Gan Z; Zhu H; Min D
Biomed Pharmacother; 2020 Aug; 128():110201. PubMed ID: 32460190
[TBL] [Abstract][Full Text] [Related]
20. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
Gu Z; Zhou Y; Cao C; Wang X; Wu L; Ye Z
Biomed Pharmacother; 2020 Sep; 129():110363. PubMed ID: 32563982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
